[Skip to Navigation]
October 1992

Current Dermatologic Therapy

Author Affiliations

Columbus, Ohio

Arch Dermatol. 1992;128(10):1422. doi:10.1001/archderm.1992.01680200134035

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


The authors write for "practitioners" a "guide for implementing effective treatment measures." "Effort has been directed... at... including the safeguards the physician should observe in prescribing [drugs]." Spironolactone is described in several sections. In the section on acne, there is a sentence describing androgen antagonism, followed by the recommended dosage. In the section on hidradenitis suppurativa, the author adds that both potassium levels and kidney function should be monitored regularly and that women of childbearing age must use contraceptive measures. In the section on hirsute women are listed the side effects: nausea, headache, and irregular menses. The author follows the statement "Treatment with spironolactone has been curtailed as this agent is possibly carcinogenic" with a treatment regimen for spironolactone without additional comment. It would be advantageous for the reader to have the full account of spironolactone in one location and references to that section elsewhere. Even with all the authors

First Page Preview View Large
First page PDF preview
First page PDF preview